Sangamo Therapeutics (NASDAQ:SGMO) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note published on Thursday morning,Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2028 earnings at $0.64 EPS.

SGMO has been the subject of several other research reports. StockNews.com initiated coverage on Sangamo Therapeutics in a research report on Sunday, July 28th. They issued a “sell” rating for the company. Barclays increased their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock traded down $0.09 during trading hours on Thursday, hitting $2.06. 3,898,286 shares of the stock were exchanged, compared to its average volume of 6,916,520. The stock has a market capitalization of $429.76 million, a P/E ratio of -2.69 and a beta of 1.10. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The business’s 50-day moving average is $1.30 and its two-hundred day moving average is $0.85.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC lifted its stake in Sangamo Therapeutics by 16.5% in the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 77,032 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Sangamo Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after acquiring an additional 57,125 shares in the last quarter. Meritage Portfolio Management raised its position in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares during the period. Golden State Equity Partners lifted its holdings in shares of Sangamo Therapeutics by 35.2% during the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 69,368 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the period. 56.93% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.